A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression

Background: Previous reports have described the effects of vagus nerve stimulation plus treatment as usual (VNS + TAU) during open trials of patients with treatment-resistant depression (TRD). To better understand these effects on long-term outcome, we compared 12-month VNS + TAU outcomes with those of a comparable TPD group. Metbods: Admission criteria were similar for those receiving VNS + TAU (n = 205) or only TAU (n = 124). In the primary analysis, repeated-measures linear regression was used to compare the VNS + TAU group (monthly data) with the TAU group (quarterly data) according to scores of the 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR30). Results: The two groups bad similar baseline demographic data, psychiatric and treatment histories, and degrees of treatment resistance, except that more TAU participants bad at least 10 prior major depressive episodes, and the VNS + TAU group bad more electroconvulsive therapy before study entry. Vagus nerve stimulation plus treatment as usual was associated with greater improvement per month in IDS-SR30 than TAU across 12 months (p < . 001). Response rates according to the 24-item Hamilton Rating Scale for Depression (last observation carried forward) at 12 months were 27% for VNS + TAU and 13% for TAU (p < .011). Both groups received similar TAU (drugs and electroconvulsive therapy) during follow-up. Conclusions: This comparison of two similar but nonrandomized TRD groups showed that VNS + TAU was associated with a greater antidepressant benefit over 12 months.